ImmuneRegen BioSciences(R) reports positive results in cancer vaccine studies

October 28, 2010

By hammersmith

[Source: Market Watch] – ImmuneRegen BioSciences, Inc.(R), a wholly owned subsidiary of IR BioSciences Holdings, Inc. /quotes/comstock/11k!irbs (IRBS 0.07, 0.00, 0.00%) , today announced that treatment with its lead compound, Homspera(R), improved the survival of animals vaccinated with an experimental melanoma vaccine.

For more information: ImmuneRegen BioSciences(R) Reports Positive Results in Cancer Vaccine Studies in Radboud University Collaboration